

Cancer Association of South Africa (CANSA)



Fact Sheet on Dermatofibrosarcoma Protuberans

Introduction

A sarcoma is a cancer that arises from transformed cells of mesenchymal origin. Malignant tumours made of cancellous bone, cartilage, fat, muscle, vascular, or haematopoietic tissues are, by definition, considered sarcomas. This is in contrast to a malignant tumour originating from epithelial cells, which are termed carcinoma. Human sarcomas are quite rare. Common malignancies, such as breast, colon and lung cancer, are almost always carcinoma.

[Picture Credit: Dermatofibrosarcoma Protuberance]



Dermatofibrosarcoma Protuberance

Dermatofibrosarcoma Protuberans (DFSP) is a rare type of cancer, a soft tissue sarcoma that develops in the deep layers of skin. It is sometimes described as having tentacles that can grow into surrounding fat, muscle and even bone. DFSP is most commonly found on the torso, but can also be seen on the arms, legs, head and neck. It has a tendency to recur in the same location after it is removed. However, it only spreads to other parts of the body in about 5% of cases.

Hussain, N., Naveed, M.Z. & Haider, G. 2015.

“Dermatofibrosarcomaprotuberans is a rare, soft tissue tumour with high rate of recurrence. It is locally aggressive, with a low rate of metastasis. Dermatofibrosarcoma Protuberance is often treated with chemotherapy and radiotherapy.”

DFSP most often starts as a small, firm patch of skin, approximately one to five centimetres in diameter. The skin is occasionally flat or depressed. It can be purplish, reddish or flesh-coloured. The tumour typically grows very slowly (over months to years) and can become a raised nodule.

DFSP tends to affect people between the age of 20 and 50, but it has been diagnosed in people of all ages. The tumours affect black patients about twice as much as white patients.

Rare Variants of Dermatofibrosarcoma (DFSP)

There are several variations of DFSP that can be identified under a microscope:

Bednar tumours (pigmented DFSP) - contain dark-coloured cells called melanin-containing dendritic cells. Melanin is the substance that gives skin its colour. As a result, this type of tumour may contain various colours, including red and brown. Bednar tumours account for approximately 1%-5% of all DFSP cases.

Myxoid DFSP - tumours contain an abnormal type of connective tissue that is called myxoid stroma. This type of tumour is uncommon, presents a diagnostic challenge and is important to recognise in order to prevent both under- and over-treatment.

Giant cell fibroblastoma - referred to as juvenile DFSP because it typically affects children and adolescents, is characterised by giant cells in the tumour. It appears to be histologically similar to DFSP and in rare instances can be found within the same tumour in conjunction with DFSP, resulting in a hybrid lesion.

Rarely, the tumours involved in the different types of DFSP can have regions that look familiar to fibrosarcoma, a more aggressive type of soft tissue sarcoma. In these cases, the condition is called Fibrosarcomatous (FS) DFSP. These tumours are more likely to metastasise than tumours in the other types of DFSP.

Incidence of Dermatofibrosarcoma Protuberance in South Africa

The National Cancer Registry (2014) does not provide any information regarding the incidence of Dermatofibrosarcoma Protuberance in South Africa.

Causes and Risks for Dermatofibrosarcoma Protuberance (DFSP)

The cause is unknown, but an injury to the affected skin may be a predisposing factor. Recent advances show tumour cells carry abnormal chromosomes within the tumour cells - t(17;22)(q22;q13) - resulting in the fusion gene COL1A1-PDGFB. This encodes a protein that causes the tumour to grow.

DFSP is rare, and affects less than 1 person in every 100 000 inhabitants per year. The tumour is rare in children. Males are affected slightly more frequently than females. There would appear to be a racial predilection towards individuals who are classified as black.

Dermatofibrosarcoma protuberans (DFSP) is associated with a rearrangement (translocation) of genetic material between chromosomes 17 and 22. This translocation, written as t(17;22), fuses part of the COL1A1 gene from chromosome 17 with part of the PDGFB gene from chromosome 22. The translocation is found on one or more extra chromosomes that can be either the normal linear shape or circular. When circular, the extra chromosomes are known as supernumerary ring chromosomes. Ring chromosomes occur when a chromosome breaks in two places and the ends of the chromosome arms fuse together to form a circular structure. Other genes from chromosomes 17 and 22 can be found on the extra chromosomes, but the role these genes play in development of the condition is unclear. The translocation is acquired during a person's lifetime and the chromosomes containing the

translocation are present only in the tumour cells. This type of genetic change is called a somatic mutation.

Diagnosis of Dermatofibrosarcoma Protuberance (DFSP)

Although routine imaging is not necessary, magnetic resonance imaging (MRI) may be helpful to evaluate the gross local extent of the tumour and may be important in preoperative planning for larger tumours.

In patients with prolonged or recurrent DFSP or when sarcomatous changes are evident (DFSP-FS (see below)) a CT of the chest should be obtained to evaluate for pulmonary metastases. A CT scan of the local area may be useful if bony involvement is suspected.

Diagnosis is made using either a core needle or an open incisional biopsy. While the role of fine needle aspiration is established in cases of recurrent disease, initial biopsies should be larger samples that demonstrate the histologic architecture of the tumour.

A core needle biopsy (or core biopsy) involves removal of a very small amount of tumour and is performed by inserting a hollow needle through the skin and into the organ or abnormality to be investigated. The needle is then advanced within the cell layers to remove a sample or core. This procedure takes a few minutes to perform and may be undertaken in an outpatient setting.

An incisional biopsy removes only a portion of the tumour for the pathologist to examine. An incisional biopsy is generally reserved for tumours that are larger and offers the pathologist a larger specimen with which to work. This type of biopsy has a slightly higher diagnostic success rate and is usually carried out in the operating room.

An excisional biopsy involves removal of the entire tumour and is typically reserved for very small lesions in which an incisional biopsy or a core needle biopsy is not practical. It is usually performed in cases where removing the entire lesion along with a narrow margin of normal tissue is easily accomplished and tolerated by the patient. This is also often performed in the operating room.

Prognosis of Dermatofibrosarcoma Protuberance (DFSP)

Because DFSP rarely spreads, this cancer has a high survival rate. Treatment is important, though. Without treatment, DFSP can grow deep into the fat, muscle, and even bone. If this happens, treatment can be difficult.

Treatment of Dermatofibrosarcoma Protuberance (DFSP)

Most cases of DFSP can be adequately treated by a dermatologist, as he or she is a specialist who routinely diagnoses and treats lesions of the skin. However, in cases of very large or advanced DFSPs, or when major reconstructive surgery is indicated, a multi-disciplinary approach may be necessary. This team may involve a dermatologist, pathologist, radiologist, oncologist, radiation oncologist,

orthopaedic surgeon (specialising in tumour surgery) and plastic surgeon (for reconstruction, if the tumour has invaded deep tissues and bone).

In determining what type of treatment is appropriate, a dermatologist will consider how deeply in to the skin the tumour has grown, where it is located on the person's body and the person's overall health.

Treatment options may include:

Mohs micrographic surgery involves removing one layer of skin at a time. Each layer that is removed is then placed under a microscope in order to look for cancer cells. The process continues until cancer cells are no longer found. The procedure is most often performed in a dermatologist's office with local anaesthesia. Because the treatment continues until cancer cells are no longer found, Mohs surgery reduces the risk that the DFSP will return.

Excision is a surgical procedure that may be utilized if a tumour is large in size. It involves surgically removing the DFSP and a portion of normal-looking skin. The procedure may be performed in a dermatologist's office or in some cases, an operating room.

Kokkinos, C., Sorkin, T. & Powell, B. 2014.

BACKGROUND:

The preferred method of treatment of Dermatofibrosarcoma Protuberance (DFSP) is surgery. Clear margins are achieved by wide local excision (WLE) or by Mohs micrographic surgery. Mohs surgery and reconstruction always requires two or more procedures. This study aims to assess the ability of WLE to accomplish clear histopathological margins and low recurrence rate with a single procedure. We present our results from ten years experience of wide local excision.

METHODS:

This is a retrospective analysis of data of all cases of DFSP treated with WLE by a single operator in our department between 2002 and 2012.

RESULTS:

Twenty patients were identified. The surgical excision and reconstruction were performed on the same day in all cases. The mean histological peripheral margin was 17 mm and the deep 9 mm. There was no incomplete excision and no recurrence recorded. There were no postoperative complications or tumour recurrences reported for an average period of 5.6 years follow-up.

CONCLUSION:

Mohs surgery offers clear histological margins but requires multiple patient visits to achieve complete excision and later reconstruction. We show that WLE can achieve these in one procedure, the excision margins making little difference when planning the eventual reconstruction.

In cases of advanced DFSP, the cancer has grown deeply and may have reached muscle or bone, even spreading to other parts of the body in rare instances. More than one treatment may be used to increase the likelihood that all of the cancer is killed or removed.

Treatment options for advanced DFSP include:

Currently, conventional chemotherapy is rarely used in the treatment of dermato-fibrosarcoma protuberans (DFSP). Limited case reports have not shown any significant value of conventional chemotherapy in the treatment of DFSP.

Systemic Therapy - while chemotherapy does not appear to be beneficial, the targeted therapy **Imatinib** has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of DFSP. It targets and turns off proteins that allow cancer cells to grow.

Radiation therapy (RT) has had a limited role in the past, but, recently, it has been used as an adjunct to surgery. Radiation therapy may be recommended for patients if the margins of resection are positive or for situations in which adequate wide excision alone may result in major cosmetic or functional deficits. Postoperative adjuvant RT may reduce the risk of recurrence when clear surgical margins are not confident. The complete radiation therapy dose ranges from 50-70 Gy. Overall, the risk of severe complications from RT is low. Close follow-up care after radiation therapy is warranted because some DFSP tumours may become more aggressive.

About Clinical Trials

Clinical trials are research studies that involve people. They are conducted under controlled conditions. Only about 10% of all drugs started in human clinical trials become an approved drug.

Clinical trials include:

- Trials to test effectiveness of new treatments
- Trials to test new ways of using current treatments
- Tests new interventions that may lower the risk of developing certain types of cancers
- Tests to find new ways of screening for cancer

The South African National Clinical Trials Register provides the public with updated information on clinical trials on human participants being conducted in South Africa. The Register provides information on the purpose of the clinical trial; who can participate, where the trial is located, and contact details.

For additional information, please visit: www.sanctr.gov.za/

Medical Disclaimer

This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this Fact Sheet. So far as permissible by law, the Cancer Association of South Africa (CANSA) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this Fact Sheet.

Whilst CANSA has taken every precaution in compiling this Fact Sheet, neither it, nor any contributor(s) to this Fact Sheet can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this Fact Sheet.



Sources and References Consulted or Utilised

American Academy of Dermatology

<https://www.aad.org/public/diseases/skin-cancer/dermatofibrosarcoma-protuberans>

British Association of Dermatologists

<http://www.bad.org.uk/shared/get-file.ashx?id=159&itemtype=document>

CancerIndex

<http://www.cancerindex.org/clinks2sd.htm>

Dermatofibrosarcoma Protuberance

<http://ispub.com/IJO/8/2/14075>

DermNet NZ

<http://www.dermnetnz.org/lesions/dfsp.html>

Genetics Home Reference

<https://ghr.nlm.nih.gov/condition/dermatofibrosarcoma-protuberans#genes>

Hussain, N., Naveed, M.Z. & Haider, G. 2015. Re-current dermatogibrosarcoma protuberans of the chest wall. *J Pak Med Assoc.* 2015 Mar;65(3):324-6.

Kokkinos, C., Sorkin, T. & Powell, B. 2014. To Mohs or not to Mohs. *J Plast Reconstr Aesthet Surg.* 2014 Jan;67(1):23-6. doi: 10.1016/j.bjps.2013.08.022. Epub 2013 Sep 6.

Medscape

<http://emedicine.medscape.com/article/1100203-treatment>

National Cancer Institute

<http://www.cancer.gov/clinicaltrials/learningabout/what-are-clinical-trials>

<http://www.cancer.gov/about-cancer/treatment/clinical-trials>

The Liddy Shriver Sarcoma Initiative

<http://sarcomahelp.org/dermatofibrosarcoma-protuberans.html>

UpToDate

<http://www.uptodate.com/contents/dermatofibrosarcoma-protuberans-epidemiology-pathogenesis-clinical-presentation-diagnosis-and-staging>

Wikipedia

<https://en.wikipedia.org/wiki/Sarcoma>